|

CRISAL Study:Cancer Risk In Secreting Adrenal Lesions

RECRUITINGSponsored by University of Roma La Sapienza
Actively Recruiting
SponsorUniversity of Roma La Sapienza
Started2024-08-27
Est. completion2024-09-30
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06520111

Summary

The aim of the present study is to report the cancer risk in secreting adrenal lesions. Secondary aims: to compare the incidence of cancer in secreting versus non-secreting adrenal lesions, in order to evaluate whether adrenal hormone activity can be considered an independent predictive indicator of malignancy; compare intraoperative and 30-day postoperative outcomes of patients undergoing adrenalectomy for secreting adrenal lesions versus non-secretoring lesions; regardless of the type of adrenal lesion, identify if there is one MIS adrenal approach that is superior to the others in terms of intra- and postoperative outcomes.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Patients undergoing elective adrenalectomy;
* Patients aged ≥ 18 years
* Acceptance of informed consent

Exclusion Criteria:

Patients undergoing emergency adrenalectomy;

* Patients aged ≤ 18 years
* Pregnant patients

Conditions4

Adrenal IncidentalomaAdrenal TumorCancerSurgery

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.